Univercells Technologies

Univercells Technologies is advancing biomanufacturing by providing innovative bioprocess technologies. The company focuses on process intensification and chaining to create cost-effective and scalable solutions for viral production.

As part of Donaldson, Univercells Technologies emphasizes life sciences and bioprocessing. Their product offerings include the scale-X™ bioreactor, which uses intensified fixed-bed technology for scalable viral production, and the NevoLine™ Upstream platform, an integrated and automated solution for intensified virus manufacturing.

Univercells Technologies is committed to enhancing process design and optimization. They leverage small-scale parallel bioreactor systems to increase production capacity and quality. Their scale-X fixed-bed bioreactor supports suspension-based viral vector production, exemplified by the transfer of shake flask processes for Adenovirus production using HEK293 cells.

The company also introduces innovative approaches like real-time biomass estimation in fixed-bed bioreactors, allowing for accurate cell density measurements. Their collaboration with Repligen Corporation enables real-time monitoring of glucose and lactate in scale-X™ bioreactors, enhancing viral vector and vaccine biomanufacturing.

Univercells Technologies supports customer manufacturing success through durable solutions and continuous innovation, ensuring their technologies are built to last.